Engflag

Meloxicam-OBL

Quick links to important sections

Meloxicam-OBL

Selected form

Meloxicam-OBL_EN

Method of action: Analgesic, Anti-Inflammatory, Antipyretic, Cox Inhibitory, Nonsteroidal Anti-Inflammatory, Pain Reliever

Treatment option: Ankylosing Spondylitis, Arthritis,Osteoarthritis, Pain, Osteoarthritis, Rheumatoid Arthritis, Spondylitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meloxicam-OBL

Property Description
Active ingredient Meloxicam
Form Oral tablet, oral suspension, intravenous solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Symptomatic treatment for pain and inflammation
Origin Synthetic (oxicam derivative)

1. What is Meloxicam-OBL and What Pharmacological Class Does it Belong To?

Meloxicam-OBL is a prescription-only pharmaceutical preparation containing the active ingredient Meloxicam, which belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class. Chemically, the entity is defined as an oxicam derivative, part of the enolic acid group of anti-inflammatory agents. The prescription-only status, a key differentiating factor, means dispensing requires professional supervision.

The substance is recognized in pharmacological studies as a preferential COX-2 inhibitor. This means that, unlike traditional NSAIDs, it exhibits a preference for inhibiting the enzyme primarily associated with inflammatory responses. Meloxicam exhibits substantial anti-inflammatory activity, along with analgesic activity and antipyretic activity.

2. Composition, Origin, and Available Drug Forms

The formulation utilizes Meloxicam as the single product active ingredient, a completely synthetic compound manufactured in a laboratory. This active substance is packaged in various common dosage form(s) to facilitate different route(s) of administration. These forms include the frequently prescribed oral tablet, the liquid oral suspension (often preferred for certain patient groups), and the specialized intravenous (IV) solution.

For the oral tablet form, the Meloxicam is combined with solid excipients, while liquid preparations utilize an aqueous solution vehicle. The availability of multiple physical forms ensures flexibility in delivering the identical core active substance.

3. The General Therapeutic Purpose of Meloxicam

The general therapeutic purpose of Meloxicam is to provide symptomatic treatment by combining its three core physiological actions to achieve comprehensive inflammation relief and pain relief. A typical use scenario involves managing pain and swelling where a continuous, long-acting effect is desired.

Meloxicam achieves its mechanism of effect by intervening in the body's inflammatory cascade. It works by reducing the production of specific inflammatory chemical messengers, known as prostaglandins, through the inhibition of cyclooxygenase. This core function allows the medicine to mitigate the physical discomfort associated with inflammation and provide effective relief.

Regulatory References

  1. NIH National Library of Medicine
  2. MedlinePlus Drug Information

What side effects are possible with Meloxicam-OBL?

Possible side effects and safety information

Meloxicam-OBL's official safety profile, as documented in regulatory sources, highlights the potential for serious adverse reactions, which often guides its use. As an NSAID, the most significant safety concerns involve the gastrointestinal and cardiovascular systems.

Serious Adverse Reactions

Official labels contain prominent warnings regarding potentially fatal serious cardiovascular thrombotic events, including myocardial infarction and stroke, where risk may increase with the duration of use. Furthermore, there is a documented risk of serious gastrointestinal events, such as bleeding, ulceration, and perforation of the stomach or intestines. Serious, life-threatening skin reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented.

Common Adverse Reactions and Organ Systems

Adverse reactions are formally classified by frequency and system. Reactions documented as 'Most Common' or 'Common' include gastrointestinal symptoms such as dyspepsia, nausea, and abdominal pain, alongside nervous system effects like headache and dizziness. Adverse effects are formally categorized across several systems, including Gastrointestinal, Nervous System, Skin and Subcutaneous Tissue, Cardiac and Vascular, and Renal and Urinary Disorders.

Classification Examples of Reactions
Most Common / Common Dyspepsia, nausea, abdominal pain, headache, edema
Serious / Rare GI bleeding/ulceration, heart attack, stroke, SJS/TEN

Safety Considerations for Specific Groups

The regulatory profile includes specific safety constraints for certain populations. Older adults are identified as having a greater risk for serious gastrointestinal events. The medicine is not recommended for use in individuals with severe renal impairment, severely impaired liver function, or in late pregnancy (from 30 weeks gestation) due to potential fetal risk. Use is also formally contraindicated for the treatment of peri-operative pain after Coronary Artery Bypass Graft (CABG) surgery.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Meloxicam-OBL

Overdose Scope

Documented overdose presentations: Acute overdose may initially present with mild symptoms, including nausea, vomiting, epigastric pain, lethargy, and drowsiness.

Physiological systems affected (as stated in label): The regulatory profile documents potential effects on the Gastrointestinal, Renal, Hepatic, Central Nervous, and Cardiovascular systems.

Dose-related or exposure-related factors (if applicable): The development of severe systemic outcomes is associated with high overexposure, emphasizing a dose-dependent severity risk.

Population-specific overdose notes (if applicable): The elderly population is noted in regulatory warnings to have an increased risk for severe gastrointestinal complications, a critical consideration in overdose management.

Emergency-response statements (as written in official documents): Management is strictly symptomatic and supportive treatment, as no specific antidote is known. Cholestyramine may be used as a procedural measure documented to accelerate the clearance of the medicine.

When immediate medical help is required (label-derived phrasing only): Patients must seek immediate medical attention for any suspected overdose. Contact emergency services immediately if severe clinical manifestations, such as signs of Gastrointestinal bleeding, coma, convulsions, or cardiac arrest, are present.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents): Non-severe (mild GI/CNS symptoms) versus Severe (critical systemic events).

Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information and Summary of Product Characteristics (SmPC).

Overdose-context constraints (as defined in official documents): Hospital monitoring is required due to the risk of severe complications.

Resulting Overdose Structure

Official overdose statements:

  • Overdose commonly presents with mild gastrointestinal and CNS symptoms, which are generally reversible with supportive care.
  • Severe poisoning can lead to life-threatening outcomes, including acute renal failure, hepatic dysfunction, and cardiovascular collapse.
  • Immediate medical attention is required for any suspected overdose; patients must contact emergency services for severe manifestations.

Connection to the overall overdose profile (2–4 sentences): The official regulatory overdose profile defines the two distinct severity classifications: mild, generally reversible symptoms and the risk of severe, life-threatening systemic complications. This classification explicitly mandates that all cases require a patient to seek immediate medical attention, focusing management entirely on supportive treatment and monitoring given the lack of a specific antidote.

Therapeutic Uses of Meloxicam-OBL

What Meloxicam-OBL Treats: Main Uses and Benefits

Meloxicam-OBL is commonly used to address symptoms related to inflammatory or irritative states, providing supportive relief in various clinical contexts. This medication is relevant for easing symptoms associated with chronic inflammatory joint conditions, including Osteoarthritis (OA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), and Juvenile Idiopathic Arthritis (JIA) in appropriate patient groups. It helps manage discomfort across conditions characterized by periods of heightened symptoms.

The main therapeutic benefit of its use is providing symptomatic support for symptoms that interfere with daily functioning, such as pain, joint tenderness, swelling, and physical stiffness. It is applied during phases when symptoms become more noticeable, such as acute flare-ups or when supportive assistance is needed post-procedure. This use contributes to improved day-to-day comfort and supports patients during difficult episodes by easing distress.

Quick Fact: Relief for Inflammation-Driven Discomfort

Meloxicam-OBL is applied in scenarios where additional management of discomfort is required, may assist with supporting functional stability and helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Meloxicam-OBL eligibility is strictly defined by regulatory documents, categorizing individuals into approved, restricted, or contraindicated populations. The medicine is officially approved for use in adults and for pediatric patients ge 2 years old for the treatment of Juvenile Idiopathic Arthritis (JIA).

ABSOLUTE CONTRAINDICATIONS POPULATION RESTRICTIONS
Known allergy or hypersensitivity to Meloxicam, aspirin, or any other NSAID. Use is generally not recommended in patients with advanced renal disease or in children under 2 years of age.
Treatment of peri-operative pain for Coronary Artery Bypass Graft (CABG) surgery. Older adults are designated as a high-risk population for serious gastrointestinal and cardiovascular events.
Severe heart failure, severely impaired liver function, or non-dialysed severe renal failure. The drug is contraindicated in the third trimester of pregnancy and should be used with caution during lactation.
Active or history of recurrent peptic ulceration or GI haemorrhage. Specific limitations apply to the maximum dose for patients undergoing haemodialysis.

This profile establishes that eligibility is based on a patient's fundamental physiological status and specific comorbidity history, ensuring prohibition for the highest-risk populations as documented in official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Meloxicam-OBL focuses on managing risks associated with combined pharmacological effects and altered drug exposure, as documented in regulatory labeling.

Pharmacodynamic and Contraindicated Combinations

Co-administration with Aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is not recommended due to a documented increase in the risk of serious gastrointestinal events. Meloxicam-OBL carries an additive risk of bleeding when used with Anticoagulants (like Warfarin), Antiplatelet agents, Oral Corticosteroids, or SSRIs/SNRIs. This pharmacodynamic effect is noted in official documents. Furthermore, Meloxicam-OBL may diminish the effectiveness of antihypertensive agents, including ACE-Inhibitors and ARBs, and may increase the risk of renal function deterioration when combined with Diuretics or Cyclosporine.

Pharmacokinetic and Exposure Effects

Official labeling documents that Meloxicam-OBL can increase the systemic exposure and thus the toxicity risk of certain co-administered medicines. This is the case with Lithium and Methotrexate, whose renal clearance is reduced, leading to elevated plasma concentrations. Conversely, the co-administration of Cholestyramine significantly decreases Meloxicam-OBL’s total exposure (AUC) by interfering with its recirculation. The oral tablet form can be taken without regard to the timing of meals or antacids. The risk of renal function deterioration with ACE-Inhibitors or ARBs is specifically noted as higher in elderly or volume-depleted patients.

Mechanism of Action

Targeting Prostaglandin Synthesis via COX-2 Inhibition

The primary mechanism of Meloxicam is the preferential inhibition of the Cyclooxygenase-2 ( COX-2) enzyme. This molecular action prevents the conversion of arachidonic acid into prostaglandins , which are chemical mediators of the body's inflammatory and fever responses. This mechanism is primarily relevant in systems where targeted pathway adjustment is required to modulate signaling within the affected pathways.

Attenuation of Pain Signaling Cascades

By lowering the local concentration of prostaglandins, the drug alters the nociceptive (pain signaling) cascade. This process specifically reduces the sensitivity of peripheral pain receptors (nociceptors), whose sensitivity is heightened by prostaglandin activity. This resulting physiological effect contributes to a reduction in heightened signaling within the targeted pathways, resulting in attenuation of pain signaling and inflammatory responses.

Central Action and Mechanistic Constraints

Meloxicam also exerts a central effect by reducing prostaglandin synthesis in the hypothalamus, thereby modulating the processes that elevate body temperature. A mechanistic constraint exists in the drug's secondary inhibition of constitutive COX-1, which, particularly at high doses or in compromised states, can interfere with homeostatic feedback mechanisms that regulate physiological functions, including the maintenance of renal blood flow.

Dosage and Administration Information

How Meloxicam-OBL is Used: Official Administration Guidelines

Meloxicam-OBL is administered based strictly on the official instructions detailed in prescribing information. The overarching principle for its use is to employ the lowest effective dosage for the shortest duration necessary to meet individual treatment goals.

Approved Administration Routes and Dosing

The medication is approved for use via two primary routes, each with specific maximum dosage limits:

Route Indication Context Standard Adult Dosing Range Maximum Dose
Oral (Tablet/Suspension) Chronic conditions (e.g., OA, RA) 7.5 mg once daily 15 mg once daily
Intravenous (IV) (Injection) Acute pain management N/A 30 mg once daily

The daily dose is always to be administered as a single dose; doses must not be divided throughout the day.

Key Administration Instructions

Administration conditions, frequency, and preparation steps are governed by the drug's label:

  • Frequency: The standard dosing schedule is once daily, with a 24-hour interval between administrations.
  • Timing: Oral Meloxicam can generally be taken without regard to the timing of meals, though some national labels advise taking it with food.
  • IV Procedure: The intravenous formulation must be administered as an intravenous bolus injection over 15 seconds.
  • Suspension: The oral suspension requires gentle shaking before measuring the dose.

Population-Specific Use Rules

Specific adjustments are mandated for certain patient groups:

  • Patients on Hemodialysis: The maximum daily oral dose is strictly limited to 7.5 mg per day.
  • Pediatric (JIA): The dose is weight-based, typically 0.125 mg/kg once daily, with a maximum of 7.5 mg per day. The oral suspension is often recommended for pediatric use to ensure accurate measurement.

These official instructions define the standardized, non-advisory protocol for using the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Meloxicam-OBL

Evidence for Chronic Inflammatory Joint Conditions (OA, RA, AS)

The research base for the active ingredient Meloxicam in adults with chronic joint conditions, specifically Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS), is primarily composed of Randomized Controlled Trials (RCTs). These short-term trials explored how symptoms change over time and included comparisons against placebo and other active non-steroidal anti-inflammatory drugs (NSAIDs). Studies examined conditions marked by functional limitations, tracking outcomes related to physical discomfort and daily functioning. Findings describe patterns observed in the studies related to changes measured in pain intensity, joint tenderness, and overall patient assessments.

Evidence for Juvenile Idiopathic Arthritis (JIA)

Research also examined the active ingredient Meloxicam in pediatric patients (children ages 2 to 16) diagnosed with Juvenile Idiopathic Arthritis (JIA). These controlled trials monitored patient-reported outcomes describing perceived discomfort in conditions involving periods of heightened symptoms. Studies utilized specific measures like the ACR pediatric 30% improvement criteria to track how symptoms evolved in the observed populations. Data for children under age two remain insufficient, as this group was generally not included in the main regulatory trials.

Overview of Long-Term Studies and Sustained Observation

The initial evidence was largely derived from short-term research exploring symptom changes, typically lasting 6 to 12 weeks. Beyond this, some trials included longer follow-up components, with studies observing responses over defined time intervals extending up to approximately one year (52 weeks). These longer observational settings evaluating daily-life functioning were used to observe patterns in the studied populations over time.

Known Gaps and Research Uncertainty

The research base includes documented areas where more data or clarity is needed. Evidence is limited concerning very long-term outcomes (beyond one year) regarding continued symptomatic relief. Regulatory reviews have noted that the evidence quality varies across studies, and certainty remains low regarding evidence for groups that were excluded from the main trials, meaning results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Meloxicam-OBL (FAQ)

Q: How quickly does Meloxicam-OBL typically start reducing pain or swelling?

A: According to official product information, when taking an oral dose, the medicine's mean maximum concentration in the blood is typically reached within two to six hours after administration. This timeframe indicates when the highest level of the medicine is typically measured in the blood after a single dose.

Q: What are the specific signs of a serious stomach issue or internal bleeding related to Meloxicam-OBL?

A: Official regulatory information warns that serious gastrointestinal issues, such as internal bleeding, can occur. Specific signs to be aware of include black, bloody, or tarry stools, or any instance of coughing up blood or vomit that resembles coffee grounds.

Q: Does Meloxicam-OBL interact with common blood pressure medications?

A: Regulatory labeling notes that the medicine may diminish the effect of certain high blood pressure medications, specifically mentioning drugs like ACE-Inhibitors and ARBs. There is also a noted risk that combining it with diuretics may increase the risk of kidney function deterioration.

Q: Why might a doctor prescribe a stomach protector (like omeprazole) along with Meloxicam-OBL?

A: The primary reason for considering a stomach protector is to mitigate the documented risk of serious gastrointestinal events. Official product information for Meloxicam-OBL includes warnings regarding the potential for bleeding and ulceration in the stomach or intestines.

Q: Are there specific food restrictions while taking Meloxicam-OBL?

A: The official prescribing information states that the oral tablet form can generally be taken without regard to the timing of meals. Food intake is not noted to change how much of the medicine is absorbed by the body.

Q: What should be done if a dose of Meloxicam-OBL is missed?

A: If a dose is missed, official patient information describes procedures for either taking the dose upon realizing or skipping it if the next scheduled dose is near. Two doses are not to be taken at the same time.

Q: What is the expected duration of effect for a single dose of Meloxicam-OBL?

A: The medicine's long-acting nature supports its once-daily dosing schedule. Pharmacokinetic studies describe the mean elimination half-life—the time required for half the dose to leave the body—as typically ranging between 13 and 25 hours after administration.

Q: Is Meloxicam-OBL used to treat chronic long-term conditions or only short-term pain?

A: The drug is officially approved for the symptomatic treatment of both chronic long-term conditions such as Osteoarthritis and Rheumatoid Arthritis, as well as for the acute management of moderate-to-severe pain. The specific formulation used may differ based on the treatment context.

Q: Can Meloxicam-OBL be used for conditions other than arthritis, like general muscle soreness or headaches?

A: Regulatory documents list the medicine's specific approved uses, which primarily include chronic joint conditions such as Osteoarthritis, Rheumatoid Arthritis, and JIA in children. It is also approved for the short-term management of moderate-to-severe pain where an injectable form is required.

Q: How does Meloxicam-OBL affect blood pressure?

A: Official regulatory information includes a specific warning that NSAIDs, which includes Meloxicam-OBL, have the potential to cause a new onset of high blood pressure (hypertension). For patients who already have high blood pressure, the medicine may also cause their condition to worsen.

Q: Are changes in liver enzyme levels a reported effect of taking Meloxicam-OBL?

A: The medicine's label includes a warning regarding potential Hepatotoxicity—damage to the liver. Regulatory documentation advises that if abnormal liver tests persist or worsen, or if clinical signs of liver disease develop, use should be discontinued.

Q: Can Meloxicam-OBL impact kidney function, and how is this monitored?

A: Meloxicam-OBL is associated with a risk of Renal Toxicity, which means potential harm to the kidneys. Regulatory documents advise that kidney function should be monitored in specific patient groups, such as those with existing kidney or liver impairment, heart failure, or dehydration.

Q: Is weight gain listed as a potential side effect of Meloxicam-OBL in official documentation?

A: While weight gain is not explicitly listed, edema (fluid retention) is noted as a common adverse reaction in the official safety profile. Fluid retention can lead to associated changes in body weight.

Q: What are the official guidelines about drinking alcohol while using Meloxicam-OBL?

A: Official regulatory guidance advises patients to avoid or limit drinking alcohol while using the medicine. This caution is due to the fact that alcohol consumption can increase the risk of stomach bleeding, which is a documented serious side effect of Meloxicam-OBL.

Q: Is it permissible to use Meloxicam-OBL with acetaminophen (Tylenol)?

A: There are no known drug interactions between Meloxicam-OBL and acetaminophen (Tylenol) noted in the regulatory documents. However, patients are cautioned to adhere strictly to the recommended daily dosages of acetaminophen to avoid the separate risk of liver damage.

Q: What is the guidance on using Meloxicam-OBL while breastfeeding?

A: The official prescribing profile states that the medicine should be used with caution during the period of lactation (breastfeeding). Regulatory documents emphasize that the potential benefits and risks must be assessed by a healthcare professional for both the mother and the child.

Q: Are there any official reports or studies on the use of Meloxicam-OBL and male fertility?

A: Regulatory nonclinical toxicology studies have addressed the potential for Impairment of Fertility. Based on the medicine's mechanism, use may cause a reversible delay in ovulation in female animals, and regulatory information notes the potential human relevance of this finding.

Q: Is it true that Meloxicam-OBL is not recommended for immediate relief of acute pain?

A: The intravenous (IV) formulation of the medicine carries a specific Limitation of Use in its official label. Due to a delayed onset of pain relief, the IV form is not recommended when the patient requires immediate, rapid relief for acute pain.

Q: Can Meloxicam-OBL mask the symptoms of an existing infection or fever?

A: Official documents include a warning that the drug's intended action of reducing inflammation and fever may inadvertently mask the typical signs of an existing infection. This means that a patient may not recognize symptoms that would normally aid in detecting an infection.

Q: What is the meaning of 'off-label use' of a drug?

A: Off-label use is a regulatory term describing when a healthcare provider prescribes a legally marketed medicine for a purpose, dosage, or population that is not specifically listed in the drug's official labeling approved by governmental authorities.

Q: Is there a known link between Meloxicam-OBL and mood changes or difficulty sleeping?

A: Official regulatory documents list potential effects on the nervous system as adverse reactions. These include drowsiness, dizziness, headache, and insomnia (difficulty sleeping), with rare reports of depression also documented.

Q: Is it possible to experience ringing in the ears (tinnitus) while taking Meloxicam-OBL?

A: Tinnitus, which is described as a ringing or buzzing sensation in the ears, is listed in the official safety profile for the medicine. This is typically documented as a post-marketing or rare adverse reaction.

Q: If I have a history of inflammatory bowel conditions, such as Crohn's disease, can I use Meloxicam-OBL?

A: Official contraindications strictly prohibit use for individuals with a history of recurrent peptic ulceration or gastrointestinal haemorrhage. The official regulatory profile requires consultation with a healthcare provider regarding use, given the general warnings for serious gastrointestinal risk associated with NSAIDs.

Q: What are the risks of using Meloxicam-OBL if a patient is dehydrated?

A: Official regulatory warnings emphasize that patients must be well hydrated before taking the medication. Using the medicine while dehydrated or volume depleted may carry a risk of deterioration of renal (kidney) function.

Q: Is the liquid form of Meloxicam-OBL dosed differently than the tablet form?

A: The oral suspension (liquid) and the tablet forms are generally considered bioequivalent and share the same total milligram dosing limits. However, the regulatory documentation notes that some formulations are not interchangeable, and patients are advised to follow the specific instructions provided for their prescribed form.

Q: What is the information on using Meloxicam-OBL if I have diabetes or high cholesterol?

A: Official warnings regarding cardiovascular risk, such as heart attack and stroke, state that this risk may be higher in individuals with certain pre-existing conditions. These noted risk factors often include conditions like diabetes and high cholesterol.

Q: What is the risk of overdose associated with Meloxicam-OBL?

A: Official documents list the potential symptoms that may occur in the event of an overdose. The regulatory guidance is to seek emergency medical attention or contact a poison help line immediately if an overdose is suspected.

Q: Can a patient stop taking Meloxicam-OBL suddenly, or is a tapering schedule generally suggested?

A: Regulatory information focuses on using the medicine for the lowest effective dose for the shortest possible duration, and typically does not contain instructions for a tapering schedule. Information on discontinuation should be obtained from a healthcare provider before stopping any prescribed medication.

Q: Does Meloxicam-OBL interact with herbal supplements?

A: The official labeling advises informing the provider about all other medications, vitamins, and herbal products they are taking. This is because some herbal products may interact with the medicine, especially those that affect the body’s bleeding or kidney function.

Q: Is blurred vision a potential side effect listed for Meloxicam-OBL?

A: Visual disturbances and blurred vision are documented as potential side effects in the official safety profile. These effects are generally classified under rare adverse reactions.

Q: What is a Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and how is it related to Meloxicam-OBL?

A: DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) is a documented serious skin adverse reaction associated with NSAIDs like Meloxicam-OBL. Regulatory documents describe it as often presenting with symptoms such as fever, rash, swollen lymph nodes, and/or facial swelling.

Q: Why is it important to read the ingredient list of over-the-counter cold and flu medicines when taking Meloxicam-OBL?

A: It is important because many over-the-counter cold and flu medicines contain other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Co-administration with other NSAIDs is not recommended in official labeling due to a documented increase in the risk of serious gastrointestinal events.

How should Meloxicam-OBL be stored and disposed of?

How to Store and Dispose of Meloxicam-OBL

Official Storage Requirements

Meloxicam must be stored at Controlled Room Temperature, typically 20, C to 25, C (68, F to 77, F). The medication must be protected from both excessive heat and moisture, and users must be careful not to store the product where it could freeze.

Keep the medicine in its original container and ensure the cap is tightly closed to maintain product integrity. All medication must be kept out of the reach and sight of children, often requiring storage in a locked cabinet or secure location.

Disposal Instructions

Unused or expired Meloxicam should be disposed of through an official drug take-back program if one is available locally. If a take-back program is not available, do not flush the medicine down a toilet or sink. The official regulatory method is to mix the tablets with an undesirable substance (such as used coffee grounds or cat litter), place the mixture in a sealed container, and then discard it in the household trash. This prevents accidental exposure and adheres to environmental release guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagRussia

Equivalent of Meloxicam-OBL found in:

A-Z Index: